Previous Close | 264.07 |
Open | 264.10 |
Bid | 262.65 x 200 |
Ask | 262.79 x 100 |
Day's Range | 262.58 - 265.92 |
52 Week Range | 211.71 - 329.72 |
Volume | |
Avg. Volume | 2,926,216 |
Market Cap | 140.933B |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | 21.05 |
EPS (TTM) | 12.48 |
Earnings Date | May 02, 2024 |
Forward Dividend & Yield | 9.00 (3.43%) |
Ex-Dividend Date | May 16, 2024 |
1y Target Est | 288.28 |
Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.